Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr raises $90M to rewrite treatment of rare muscle disease
(3h)
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
(4h)
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
(5h)
Abbott teams with Google Health on AI-powered health insights app
(10h)
Regeneron backs $75M series A for antibody upstart Infinimmune
(21h)
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
(1d)
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
(1d)
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
(1d)
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
(1d)
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
(1d)
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
(1d)
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
(1d)
Labcorp nabs FDA green light for BRAF melanoma diagnostic
(1d)
FDA issues alert in wake of BD recall of faulty needle sets that caused four deaths
(1d)
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
(1d)
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
(1d)
Silence brings the noise to Takeda with phase 2 blood cancer win
(1d)
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
(1d)
Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub
(1d)
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
(4d)
BioPharma Dive
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
(1h)
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
(4h)
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
(5h)
Trump signs order seeking to upend childhood vaccine schedule
(6h)
Vaderis hauls in $152M to test an AKT-targeting drug
(6h)
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
(1d)
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
(1d)
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
(1d)
Regulatory operations: The overlooked half of submission readiness
(1d)
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
(4d)
Why Big Pharma is chasing the industry’s most-powerful supercomputer
(4d)
Latigo IPO raises nearly $350M for pain drug development
(4d)
Replimune rebounds to win FDA approval of melanoma drug
(4d)
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
(5d)
Takeda approval ushers in new wave of sleep drugs
(5d)
Erica Schwartz confirmed as next CDC director
(5d)
With $263M, LifeMine unearths a new drug for organ transplants
(5d)
FDA approves Moderna’s mRNA flu vaccine
(5d)
Cardiac drug developer Braveheart banks more than $382M in IPO
(5d)
Attovia adds to biotech IPO momentum with $289M offering
(6d)
Endpoints News
Two health insurers give an AI reality check
(2h)
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
(3h)
Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says
(4h)
Epicrispr secures $90M after early data on epigenetic FSHD treatment
(4h)
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
(5h)
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
(6h)
Trump directs MMR vaccine to be split in three parts, backs autism claim
(21h)
FDA rejects ITM's radiopharma drug over manufacturing problems
(22h)
Bristol Myers details new $2.3B manufacturing campus in Houston
(23h)
Judge blocks enforcement of WuXi AppTec's designation as Chinese military company
(1d)
Scholar Rock drops Novo manufacturing site from SMA drug application
(1d)
Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
(1d)
AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
(1d)
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
(1d)
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
(1d)
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
(1d)
BioNTech vets get $25M seed funding for virtual cancer surveillance startup
(1d)
Is China’s work ethic a ‘wake-up call’?; The megamerger that wasn’t; and more
(3d)
BINSA legislation to limit biotech deals in China unveiled in Senate
(4d)
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
(4d)
BioSpace
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
(3h)
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
(4h)
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
(5h)
Epicrispr, Infinimmune snag combined $165M in VC cash
(5h)
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
(6h)
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
(6h)
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
(6h)
Austria’s new growth fund could further bolster its dynamic biotech innovation economy
(10h)
BMS picks Texas for new $2.3B manufacturing campus
(1d)
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
(1d)
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
(1d)
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
(1d)
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
(1d)
Tenax shares nosedive as heart failure drug fails in Phase 3
(1d)
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
(1d)
Denali climbs past Avlayah expectations with $3.6M in revenue
(1d)
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
(1d)
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
(1d)
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
(1d)
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
(1d)
STAT News
Trump is counting on the health care industry to remake vaccines. They’re pushing back instead
(51m)
Trump says his executive order should restore trust in vaccines. It does the exact opposite
(1h)
How we know that splitting up the MMR vaccine could be dangerous
(3h)
Trump’s vaccine pivot overshadows food rule
(3h)
We’re reading about an FDA rejection, 340B court battles, and more
(4h)
A RAPID proposal for breakthrough coverage, and nurses push back on AI
(4h)
Skylar Bio kicks off new gene therapy trial for deafness
(5h)
Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
(9h)
Nurses seek a seat at the table as they fight expanding clinical AI
(9h)
Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
(9h)
The new geography of abortion care
(9h)
IRBs have a problem. Can North Star’s nonprofit model save it?
(9h)
Trump returns to controversial vaccine policy with order questioning childhood schedule
(22h)
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
(1d)
FDA to require notice of additives in food supply for the first time
(1d)
Ban prior auth? And hospitals cut jobs
(1d)
FDA panel to weigh Grail’s Galleri test
(1d)
We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
(1d)
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
(1d)
Heart failure drug from Tenax Therapeutics fails in pivotal study
(1d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(3mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(4mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(4mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(4mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(4mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(4mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(4mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(4mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(4mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(4mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(4mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(4mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(4mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(4mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(4mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(4mo)
Drug Channels
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(7h)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1d)
A System of Record, or a System of Learning?
(4d)
Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts
(1w)
The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.
(2w)
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(2w)
Direct-to-Patient: Transforming the Manufacturer Access Model
(3w)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(3w)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(3w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(4w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(4w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(4w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(4w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(4w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(4w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(4w)
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(1mo)
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(1mo)
The Hidden Cost of 340B for Employers and Health Plans
(1mo)
The Hidden Cost of 340B for Employers and Health Plans
(1mo)
European Biotechnology Magazine
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
(1d)
Clinical Development Expert has started
(4d)
Actimed retrieves ALS drug after Faraday collapse
(5d)
Mironid lands $46M Series B to take kidney drug into clinic
(5d)
Evexta pairs ex-Merck drug with Roche’s giredestrant
(1w)
AstraZeneca taps Pathos for breast cancer degrader
(1w)
Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
(1w)
Sobi’s dealmaker CEO exits after global expansion
(1w)
AstraZeneca explores $400B combination with BMS
(1w)
ZEUS failure clouds future of Novo’s cardiovascular plans
(2w)
Pharmanovia licenses China-approved PARP drug for up to €423.5M
(2w)
Relation deepens GSK alliance with $110M deal
(2w)
Sanofi axes two more inflammatory-disease drugs
(2w)
CHMP backs first CETP inhibitor after two decades of failure
(2w)
GSK announces plan to axe UK Stevenage R&D hub, moving to Cambridge
(2w)
Pentixapharm raises €20.4M for Phase 3 diagnostic trial
(2w)
Chiesi retreats from Gossamer PAH programme after Phase 3 miss
(2w)
Fast-track trial approval: a way to jump the EU queue?
(2w)
argenx pays $2.2B for Forte’s early autoimmune promise
(2w)
BIO-Europe 2026
(2w)
Drug Hunter
Rethinking ERα Degradation as the Driver for SERD Efficacy
(2h)
oveporexton (TAK-861)
(4d)
Regioselective Synthesis of N-Aryl Pyrazoles Stemming from an Academic-Industrial Collaboration
(5d)
BI-3406
(6d)
aleniglipron/GSBR-1290
(1w)
Are RIPTACs the Small Molecule Answers to ADCs?
(1w)
June 2026
(2w)
June 2026 Patent Gazette
(2w)
ensitrelvir (S-217622)
(2w)
BMS CAMK2 Inhibitor Patents Show a Continuing Paradigm Shift from Isoform Selectivity to Tissue Selectivity
(2w)
Module 5 Quiz
(2w)
zidebactam
(3w)
centanafadine
(3w)
thalidomide
(3w)
18F-florquinitau
(3w)
The NaV1.7 Disconnect: Pharmacologic Inhibition Does Not Recapitulate Genetic Loss
(3w)
Orum’s DACs Aim to Expand the Therapeutic Window of GSPT1 Degraders
(4w)
Emerging Strategies for GSPT1 Degradation
(4w)
nibrozetone
(4w)
zovegalisib (RLY-2608)
(4w)
Labiotech.EU
Seven biotechs driving progress in Duchenne muscular dystrophy
(4h)
We asked 19 biotech leaders what breaks their deals. It wasn’t the science.
(1d)
Top biotech deals in July 2026
(4d)
Why Western pharma is sleeping on China’s circular RNA revolution
(4d)
The biggest biotech funding rounds in July 2026
(6d)
Eight CAR-T companies tackling autoimmune disorders
(1w)
Cryopreservation in cell therapy: Reducing variability from the start
(1w)
10 biotechs in Japan to watch in 2026
(1w)
Merck after Keytruda: what the pipeline looks like
(2w)
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s
(2w)
Meeting unmet needs: new treatments for gout race in the clinic
(2w)
Mouse models and CRO selection critical to de-risking neurology drug development
(2w)
Six TIL therapy companies to watch out for
(2w)
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(3w)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(3w)
Is an HIV cure possible? The future of HIV therapy
(3w)
Roche’s new gene sequencer on the market: where do current players stand?
(3w)
Inside one of Europe’s most advanced biotech innovation hubs
(3w)
Guinea worm: Why disease eradication is so rare
(3w)
How BIO-Europe is expanding beyond dealmaking in 2026
(4w)
Bio IT World
A Brain Orchestra … Playing at a Range of Unsynchronized Tempos
(12h)
New CEO for PacBio, Updated Chemistry for Vega System
(4d)
‘Reproductive Resilience Hypothesis’ Highlights the Ovary as a Discovery Source in Longevity Research
(5d)
Trends from the Trenches: Why Semantics Matter in Life Sciences
(6d)
Vibrating Capsule Reveals Gut-Brain Biomarkers for Anorexia Relapse
(1w)
Beyond Sequence: Building the Next Generation of Structural Genomics Platforms
(2w)
Follow the Money: Fresenius Expands Multiple Growth Areas, Off-the-Shelf CAR-T Therapies, Antibody for Full Season Influenza
(2w)
Baylor College Serves as Sequencing Center, Immunai, Boehringer Ingelheim Multi-Project Collaboration, Spatial Biology
(2w)
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(3w)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3w)
Different Teams, Same Problem
(3w)
Winning Best of Show Again: A Reflection on MLADU, Research Data, and the Bio-IT World Community
(3w)
With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform
(4w)
CFDE Promotes Collaboration to Build Creative and Practical Solutions to Data Challenges during the Bio-IT Hackathon
(4w)
How Sugar on Brain Cells May Be Driving Alzheimer’s and How a Common Joint Supplement May Be Making It Worse
(4w)
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(1mo)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(1mo)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(1mo)
Digital Brain Twin Tailor-Made for Autism Spectrum Disorder
(1mo)
Follow the Money: Inflammatory Bowel Disease Oral Drug, Breast, Colorectal Cancer ADCs, Other Next-Gen, Novel Treatments
(1mo)
GEN News
Bispecific Antibody Purification’s Complexity Problem and How to Fix It
(55m)
Indiana Emerges as a Leading U.S. Biopharma Hub
(3h)
How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
(4h)
The Future of Aging Research Is Longitudinal, Multiomic, and Single-Cell
(5h)
Greater Richmond’s Pharma Cluster Keeps Compounding
(5h)
BMS Chooses Houston for $2.3B Manufacturing Facility
(16h)
Bacterial Trait-Finding and Gene Mapping Platform Speeds Microbial Engineering for Biotech Applications
(19h)
Spatial Transcriptomics Uncovers Heterogeneity in Heart Transplant Rejection
(20h)
Candida auris Persists in Hair Follicles, Hijacks Immune Signaling
(23h)
BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development
(1d)
Early-Life Stress Leaves Epigenetic “Scars” That Prime Stress Sensitivity
(1d)
StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss
(1d)
Novel Molecular Glue Discovery Platform Unlocks Undruggable Cancer Targets
(4d)
FMT Shows Promise for Peanut Allergy Tolerance in Phase I Trial
(4d)
Algae-Based Food Product Development Earns Gates Foundation Award
(4d)
Genetic Findings Provide Insights Into Leading Cause of Back Pain
(4d)
Engineered Human Interneuron Transplants Repair Respiratory Circuits in Injured Rats
(4d)
Tau and Alzheimer’s Disease
(4d)
Renewed Importance of CEX in Monoclonal-Antibody Purification
(5d)
Tau Protein Linked to Mitochondrial Reverse Electron Transport in Preclinical Models
(5d)
Cure Today
Text a Survivor: Sally Kalksma on Life With Multiple Myeloma
(2h)
Weekly App Check-Ins Eased Fatigue in Metastatic Breast Cancer
(4h)
Divesiran Eliminates Need for Phlebotomy in 88% of Patients With Polycythemia Vera
(21h)
Cyclosporiasis Cases Top 6,700: What Patients with Cancer Need to Know
(22h)
When the Oncology Doctor Who Watched Over You Is Two Hours Away
(22h)
Oncology Nurse Earns Patient Trust Through Clinical Skill and Compassion
(1d)
Dr. Priscilla Merriam Explains Why Sarcomas Are Often Mistaken for Benign Growths
(1d)
"No One Should Be Alone": A Lung Cancer Advocate's Mission to Keep Her Father's Memory Alive
(2d)
Multiple Myeloma Survivor Valerie Traynham: "Survivorship Starts the Moment You Hear, 'You Have Cancer'"
(3d)
Questions to Ask Before Thyroid Cancer Surgery
(3d)
This Oncology Staff Member Remembers Every Patient's Story — and It's Transforming Care
(4d)
Thyroid Cancer Awareness: Surgery, Surveillance and Life After Treatment
(4d)
What Happens After a Lung Cancer Diagnosis
(4d)
FDA Approves Tudriqev Plus Opdivo for Advanced Melanoma That Has Progressed After PD-1 Immunotherapy
(4d)
When Insurance Denies Cancer Treatment: Finding Strength and Resilience After an Appeal Is Rejected
(5d)
9 Months After Surgery: Carolyn Rothfeld's Lung Cancer Story
(5d)
How Robotic Surgery Advances Have Enhanced Recovery in Patients With Lung Cancer
(6d)
After Breast Cancer, Finding the Time and Space to Live Again
(6d)
What Does a High-Risk Multiple Myeloma Diagnosis Mean?
(6d)
The Guilt of Telling Her Family She Had Lung Cancer: Gillian Ryan's Story
(6d)
Contract Pharma
CPHI Unveils Pharma Sustainability Summit
(2h)
ILiAD Appoints Former GSK Exec as Chief Business Officer
(3h)
Altasciences Expands Bioanalytical Labs in North America
(4h)
Cambrex Breaks Ground on $30M Milan R&D Facility
(4h)
BMS to Build $2.3B Manufacturing Campus in Houston
(1d)
Bruker Invests in Organ-on-a-Chip Firm Mimetas
(1d)
Scinai Appoints Eran Kuratz as Head of Supply Chain & Business Process Administration
(1d)
Innovent Adds Vanflyta to China Oncology Portfolio
(1d)
Jones Healthcare Group Acquires Ontario Thermoforming Facility
(4d)
Biogen Completes RayThera Acquisition
(4d)
The Friday Brief for August 7, 2026: Mergers, Launches, and Rebrands
(4d)
AstraZeneca, CSPC Establish New Biologics Manufacturing JV in China
(4d)
Mediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases
(4d)
CellFiber, Tidewave Bio to Evaluate 3D Cell Culture Platform for Scalable Manufacturing
(5d)
Safely Scaling High Potency API Manufacturing
(5d)
Evotec, Odyssey Launch R&D Partnership in Autoimmune, Inflammatory Diseases
(5d)
ILC Dover Shares Testing Results for EZJetFlo for Powder Dissolution and Mixing
(5d)
BMS to Deploy Schrödinger AI Co-Scientist Bunsen in Its Research Organization
(5d)
Porton Advanced Expands CDMO Services to Commercialization with China Manufacturing License
(6d)
NueCell Bio Launches as Specialist Partner in Cell Therapy Acceleration
(6d)
Pharma Times
Lexeo wins FDA RMAT status for LX2020
(8h)
EHP Awards 2027 open for entries
(8h)
NICE backs new blood cancer regimens
(1d)
Obsidian begins registration cohort for amsoki-cel
(1d)
Entera Bio data selected for ASBMR plenary session
(4d)
NHS backs delayed‑release treatment for cystinosis
(5d)
Oblenio doses first patients in phase 1a autoimmune trial
(6d)
BeOne Medicines secures UK innovation passport for HCC therapy
(6d)
Sanofi’s MenQuadfi approved for EU infants
(1w)
Qnovia licenses novel antimicrobial peptide
(1w)
Lexeo wins FDA RMAT status for LX2020
(1w)
Polpharma Biologics gains FDA and EMA review acceptances
(1w)
Parsortix study shows promise for ADC target detection
(1w)
Vista trial begins dosing in precision cancer vaccine study
(2w)
Lynavoy recommended for EU approval by the CHMP
(2w)
Atsena gains EMA orphan status for two gene therapies
(2w)
J&J reports major survival gains with dual‑target myeloma regimen
(2w)
OrbusNeich begins Japanese trial for drug‑coated balloon
(2w)
Nezglyal receives positive CHMP opinion supporting treatment access for boys with cALD
(2w)
Novogene Europe expands single‑cell sequencing capability in Cambridge
(2w)
Medcity News
From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust
(4h)
Which Health Tech Companies Are Getting Customer Experience Right?
(4h)
How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices
(18h)
Amazon Pharmacy Executive: Formularies are Anti-Choice
(18h)
Small Businesses Could Face Double-Digit Premium Hikes in 2027
(18h)
Jazz Pharma Expands Again in Epilepsy With $850M Actio Bio Acquisition
(19h)
MedCity Pivot: How Aetna is Adopting Agentic AI
(1d)
AI in Drug Development is Not a Data Problem — It’s An Evidence Problem
(1d)
How to Keep Clinicians Satisfied, the Ascension Way
(1d)
Compliance Alone Won’t Fix the Home Health Fraud Problem
(1d)
Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs
(1d)
MedCity FemFwd: Employer Strategies for Women’s Health
(1d)
Two Differing POVs Emerge About the Hinge-Cylinder Deal
(1d)
Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs
(1d)
Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs
(2d)
My Wish For Better Care For Americans Living in Rural Areas
(2d)
Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push
(3d)
Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
(3d)
Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements
(3d)
The Missing Piece of Preventive Dental Care Lies in the Bite
(4d)
Chemical & Engineering News
Chemistry advances when disciplines connect
(5h)
Periodic Graphics: Caterpillars vs. plants: A chemical battle
(20h)
Memory Lane: Laboratory science before safety data sheets
(22h)
Editorial: Scientific self-governance works well. Let’s not risk it
(1d)
Obituary: John Worns
(1d)
Comment: The ACS Heroes of Chemistry program turns 30
(1d)
New screening platform expands the search for molecular glues
(1d)
Lowest-ever Rhine levels disrupt chemical production
(4d)
Iran conflict lifts chemical earnings
(4d)
Policy Watch: US approves first mRNA flu vaccine
(4d)
Chemistry in Pictures: Crystal wolf
(4d)
How snails use chemistry to modify their mucus materials
(4d)
C&EN weekly chemistry news quiz, August 7
(4d)
AI program designs new bacteriophages
(5d)
Fluffy meshes clean up microplastics big and small
(5d)
California PFAS pesticide bill fails but sets groundwork, sponsor says
(5d)
This new human genome has almost no gaps
(5d)
Why Nigeria’s antibiotic leads stall at the lab bench
(5d)
How does a single cell seed metastasis?
(5d)
BCCE returns to UW–Madison to reflect back and march forward
(5d)
The Pharma Letter
CellProthera inks MoU for ProtheraCytes distribution in Japan
(3h)
Long-acting therapies continue to gain momentum in HIV
(5h)
FDA rejects ITM’s ¹⁷⁷Lu-edotreotide filing
(6h)
Pharma as its own retailer
(6h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(7h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(7h)
Silence Therapeutics' siRNA hits the mark in polycythemia vera
(7h)
MoonLake's nanobody clears Phase III test, but shares slip
(7h)
Avere Thera plans $500M placement to support AVR-001 development
(7h)
Avere Thera plans $500M placement to support AVR-001 development
(7h)
BMS investing $2.3 billion in Texas campus
(8h)
India's OPPI pushes for regulatory data protection framework
(9h)
Former World Bank president joins ImmunityBio exec team
(9h)
Jazz expands epilepsy portfolio with buy of Actio Biosciences
(1d)
Impressive top-line Phase II results for AbCellera’s ABCL635
(1d)
Sobi licenses lacutamab from Innate Pharma
(1d)
BioMarin scraps BMN 401, ending its $270 million Inozyme bet
(1d)
Oculis signs asset deal with Accure Therapeutics for privosegtor
(1d)
Almirall strengthens China footprint with CrystalO collaboration
(1d)
Samsung Bioepis lines up Opuviz syringe as European aflibercept rivals multiply
(1d)
Targeted Oncology
Study Finds Genomic Profiling Turnaround Time Improves, but Delays Persist
(19m)
Myeloma Physicians Consider Approaches to Subcutaneous Therapy
(1h)
Ravi Salgia, MD, PhD, Discusses the ADAPT-Funded IMMUNO-BIOMAP Trial in NSCLC
(4h)
Dr Salgia on Curing Advanced Non–Small Cell Lung Cancer
(19h)
FDA Advisory Committee to Review Galleri MCED Test's PMA Application
(1d)
What Biomarkers to Test for in Non–Small Cell Lung Cancer?
(1d)
Adding Ibrutinib to Liso-Cel Drives Deep Remissions in R/R CLL/SLL
(1d)
What the ENDURANCE Trial Reveals About Discontinuing Lenalidomide in Myeloma
(1d)
KRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says
(1d)
Why ePROs Are the Future of Supportive Oncology Care
(2d)
AI Model Predicts Late Distant Recurrence Risk in HR-Positive Breast Cancer
(2d)
Lessons Learned From the OncoPRO Initiative
(2d)
Inetetamab-Pyrotinib Regimen Shows High pCR in HER2-Positive Breast Cancer
(3d)
Dr Patt Reflects on the Evolution of ePRO Monitoring
(3d)
Low Physician Density, High Social Vulnerability Predict AlloHCT Gaps Across the US
(3d)
BI-1808 Receives FDA Fast Track Designation in Ovarian Cancer
(4d)
Age May Inform Risk Stratification in Alcohol-Related HCC
(4d)
Can Doctors Predict Who Immunotherapy Will Work For? City of Hope Aims to Find Out
(4d)
First Patient Enrolled in Registration-Enabling Amsoki-Cel Melanoma Cohort
(4d)
How Remote Therapeutic Monitoring Enhances Supportive Cancer Care
(4d)
MedWatch
Eli Lilly faces criticism for Danish new campaign
(4h)
Novo Nordisk launches once-weekly insulin treatment in the US
(5h)
Eli Lilly maintains plans for production facilities in Germany despite billion-dollar cuts
(8h)
Watch Media launches new media about the Nordic defence industry
(8h)
Covert Novo Nordisk-Lundbeck alliance recruits former Novo candidate and replaces CEO
(9h)
Genmab CEO ahead of legal battle with partner AbbVie: "I'm neither shocked nor intimidated"
(11h)
Eli Lilly's weight-loss tablet gets UK approval
(1d)
Novo Nordisk partners with Amazon to develop drugs faster using AI
(1d)
Chemometec signs collaboration deal with Roche Diagnostics
(1d)
Genmab is setting up sales teams despite lack of data for drug candidates
(1d)
Genmab's first new growth driver will face a crucial test this fall: “It’ll be dynamite”
(1d)
Pfizer ramps up cost-cutting plan
(1d)
Divested GN division launches new AI-based hearing aid platform
(1d)
Olympus reports strong first-quarter demand
(1d)
Novo Nordisk and Eli Lilly win US antitrust case
(1d)
Demant upgrade widely expected up to Q2 report
(1d)
Fresenius Ventures hires Danish profile to head new German healthcare fund
(1d)
Novo CEO’s rhetoric draws union criticism: “A harsh message”
(1d)
Novo Nordisk's tablet success depends on production capacity
(1d)
Novo Holdings and Sanofi invest in US COPD biotech company
(1d)
In The Pipeline
So How Is AI Drug Discovery Doing, Really?
(19h)
This Is Why We Run Trials, Unfortunately
(4d)
Put Your Money Down, They Say
(4d)
Target Practice on the Molecular Scale
(5d)
We Only Know Her as Mei
(6d)
The Gut Microbiome and Cancer Therapy
(1w)
A Friendlier Fluorination
(1w)
Bacteria and Cancer: The Latest Word
(2w)
Flatworms, Ion Channels, and Burning Mouths
(2w)
Preventing Misfolding by Preventing Folding
(2w)
Taking a Tip From Plants - For the Eyes?
(2w)
Clinical Failure Rates Over the Decades: Yikes
(3w)
The Assault On Science Funding Continues
(3w)
Thoughts on the "Netflix Analogy"
(3w)
Benchmarking the Benchmarks
(3w)
More Pancreatic Cancer Vaccine Progress - Treatment and Preventative
(3w)
More Condensate Secrets Revealed
(4w)
The Battle For Sickle Cell
(4w)
Tau In the Clinic, Again
(4w)
Amyloidosis Continues to Fight Back
(4w)
Pharmaphorum
England close to eliminating hep C thanks to treatment drive
(7h)
Trump order upturns federal childhood vaccines policy
(7h)
UK is first European country to approve Lilly's Foundayo
(9h)
Ex-BioNTech execs launch 'AI-native' cancer company
(1d)
Tenax trounced by phase 3 heart failure readout
(1d)
Jazz builds in epilepsy with $1.3bn Actio acquisition
(1d)
Novo Nordisk partners Amazon on London AI hub
(1d)
Alzheimer's patients 'not changing brain health behaviours'
(1d)
Sobi adds rare lymphoma drug with $580m Innate tie-up
(1d)
Quartet of biotechs join Nasdaq after stellar IPOs
(1d)
TransThera's resistant biliary cancer drug cleared in China
(4d)
Google defectors set up AI-based scientific method company
(4d)
Third time lucky for Replimune as FDA OKs melanoma drug
(4d)
LifeMine gets $263m for transplant drug, and other financings
(4d)
Tarsus places $800m wager on Alkeus' Stargardt therapy
(5d)
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
(5d)
Takeda's first-in-class narcolepsy drug claims FDA approval
(5d)
Senate confirms Erica Schwartz as CDC Director
(5d)
FDA clears Moderna's mRNA-based seasonal flu shot
(5d)
Sources quash rumours of an AZ/BMS mega-merger
(6d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
UK patients to benefit from approval of weight loss tablet
(1mo)
Vertex presents new data on Casgevy in children
(1mo)
DDW Highlights: 16 June 2026
(1mo)
LXR inverse agonist shows promise in liver disease
(1mo)
Guide: One solution – from R&D, to QC
(1mo)
A potentially practice-changing advance in bile duct cancer
(1mo)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(1mo)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(2mo)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(2mo)
PhoreMost advances brain cancer programme to trial
(2mo)
Oriva appoints Arbat as CEO, advances endometriosis asset
(2mo)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(2mo)
This week in Drug Discovery (8 June – 12 June)
(2mo)
Laverock reports positive data from oncology programmes
(2mo)
GSK acquires Nuvalent and cancer therapy pipeline
(2mo)
HIT Consultant
Why Digital Health Founders Should Stop Worrying if They Are “AI Enough”
(13h)
From “Maybe” to Baltic Gods: The Stories Behind Virus Names
(13h)
Kyndryl to Acquire Healthcare IT Leaders: Scaling AI Modernization Across Hospitals and Payors
(18h)
Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy
(1d)
Beyond Pack-Years: Why Lung Cancer Detection Demands a Shift to AI-Driven Case-Finding
(1d)
The Silent Breakdown of Revenue Cycle Management
(1d)
HealthSnap Secures $25M to Scale AI-Augmented Virtual Care
(1d)
CliniComp Receives FDA 510(k) Clearance for EHR-Integrated PACS Viewer
(1d)
iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform
(1d)
Three Essential Principles for Evaluating Healthcare AI Vendors
(4d)
Controlling AI Hallucinations: Building Evidence- First Trust in Medical Information and Medical Writing Workflows
(4d)
PwC and Zyter Collaborate to Deploy AI Execution Platform for Healthcare Payers and Providers
(4d)
M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix
(4d)
CCM and KLAS Research Report: 63% of Health Systems Lack Advanced AI Strategy Frameworks
(5d)
M&A: Unite Us Acquires Vircho Health to Advance Performance Analytics for Community Care Networks
(5d)
Solventum Announces Intent to Separate Health Information Systems Business
(5d)
Definitive Healthcare Launches Early Adopter Program for AI-Powered Intelligence Platform
(5d)
Transcarent Names Optum Veteran Mike Morgan as Chief Commercial Officer
(5d)
The Growing Disconnect Between Clinical Documentation and Reimbursement
(5d)
Beyond AI Scribes: Why Ambient Clinical Intelligence Is Health IT’s Greatest Governance Test
(5d)
Insights: Pink Sheet
New EU Tool Helps Drug Developers Check If They Need A Joint Clinical Assessment
(1h)
UCB Gets Scottish Funding For Zilbrysq, But England’s NICE Not Convinced
(1h)
UK MHRA Sets Diversity Goal For ‘Western Authority Dominated’ PIC/S Pharmacovigilance Group
(3h)
Trump Orders Overhaul Of Childhood Vaccination Schedule, Calls For MMR Split
(8h)
DEA Proposes Down-Scheduling Some Insomnia Drugs, Denies Idorsia Bid To Eliminate Restrictions
(20h)
Tonix Advances Lyme Antibody as Infection-Associated Chronic Illness Gains Interest
(20h)
Generic User Fee Deals Creates Domestic-Focused Incentives, Could Lower Application Fees
(23h)
Global Inspectors Prepare For AI-Powered Pharmacovigilance Era Under PIC/S
(1d)
EMA Explains Shortage Prevention Plan Rules Under Pharma Reform & Critical Medicines Act
(1d)
India Raises Stakes: Fabricated Drug Data Now Risks Permanent Market Exclusion
(1d)
National Priority Voucher Program Should Balance Speedy Reviews With Public Trust, Sponsors Say
(3d)
Medicare Codifying Eligibility Reset That Delayed Price Negotiation For ‘Deemed’ Biologics
(3d)
Moderna’s Flu Vaccine Approval Brings Postmarket Studies, Uncertain Fall Sales Season
(3d)
Pink Sheet Podcast: Regulatory Nationalism And US FDA’s IND Reforms
(4d)
Recent And Upcoming US FDA Advisory Committee Meetings
(4d)
CEPI Points Developers To 45 African Trial Sites In Race For Bundibugyo Vaccine
(4d)
‘An Early Warning Map’: Lawyer Explains EU Animal Phase Out Roadmap
(4d)
Too Many GVP Inspections, Too Little Coordination: UK-Canada Pilot Offers A Way Forward
(4d)
Replimune’s Tudriqev Rides US FDA AdComm Recommendation To Approval After Rocky Review
(4d)
National Advertising Division Clears Dupixent Ads Of Making Implied Superiority Claims
(4d)
BioXconomy
DOJ adopts targeted approach to mergers
(2h)
RNA and ethical quandaries in Spider-Man: Brand New Day
(2h)
CMS, HRSA target 340B with new payment, rebate rules
(3h)
Innate Pharma lands $580m Sobi partnership for lymphoma therapy
(3h)
Epicrispr raises $90m to advance muscular dystrophy therapy
(5h)
In perfect harmony: Jazz tunes up epilepsy portfolio with $820m Actio deal
(7h)
Medicare’s GLP-1 Bridge program redraws the weight management pricing map
(15h)
Spain continued to lead the EU in clinical trials in 2025, AEMPS reports
(23h)
FDA approves Moderna’s flu shot in first for mRNA vaccines
(1d)
Tarsus expands eye care empire with $800m Alkeus buy
(1d)
Fit to fund: UK biotech VC investment surges to five-year high
(4d)
Attovia pulls in $298m as IPO prices above proposed range
(4d)
CMS gene therapy access model shows promise, but key gaps remain, experts say
(5d)
Braveheart prices upsized $382.5m IPO for cardiomyopathy therapeutics
(5d)
Hinge Health takes a gut check: $105m Cylinder buy signals GI expansion
(5d)
AI can transform trials, but human oversight is critical, says ACRO
(6d)
Pharma megamerger speculation collapses: No AstraZeneca-BMS talks
(6d)
Expedition expedites COPD care with $115m funding boost
(6d)
Cell Summit 2026: Heralding an era of improved patient access for CGTs
(6d)
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play
(1w)
BioCentury
FIH urgency in the U.S. Plus: federated learning, biotech IPOs — a BioCentury podcast
(16h)
Jazz expands neuro reach with rare epilepsy takeout: Deals Report
(18h)
Auchincloss bill would embed trials in routine care, speed FIH starts
(18h)
Silence, AbCellera emerge as best-in-class contenders as Sionna sinks
(19h)
WuXi AppTec wins preliminary injunction in 1260H case
(2d)
Mirati vet Christensen named CEO of well-funded start-up Terremoto
(3d)
Four biotechs raise over $1.2B in strong IPO run: Public Equity Report
(3d)
FDA regulatory moves reflect a steadying ship
(3d)
Otsuka’s Voyxact raises the bar in IgA nephropathy
(3d)
Biotech in the balance: A conversation with Jeremy Levin
(4d)
LifeMine draws $263M to advance calcineurin inhibitor for transplant rejection: Venture Report
(4d)
Coultreon: Building a cleaner SIK3 inhibitor for autoimmune disease
(4d)
Science Spotlight: Base editing to reduce toxic HTT fragments
(5d)
Turning cold adaptation into metabolic medicines: Q&A with Shingo Kajimura
(5d)
Lilly widens GLP-1 injectable lead over Novo but lags on oral sales
(5d)
Former Temasek exec Alsagoff joins Flagship
(6d)
Calissa: Photodynamic therapy for durable clearance of port-wine stains
(6d)
Fixing your own house first: Academic centers on FIH trials
(6d)
AZ-BMS rumors, Replimune, psychedelics — a BioCentury podcast
(1w)
AZ investors aren’t buying it — neither am I
(1w)
SCRIP
Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO
(8h)
Stock Watch: Why Investors Sold Sanofi Despite The Headline Beat
(8h)
Tenax Sees A Path Forward For TNX-103 Despite Phase III LEVEL Miss
(20h)
Silence Makes Noise With Positive Divesiran Results In Polycythemia Vera
(20h)
Jazz Returns To Epilepsy Dealmaking With Actio Acquisition
(20h)
Pipeline Watch: Three Approvals And Two Phase III Readouts
(1d)
Quick Listen: Scrip’s Five Must-Know Things
(1d)
Braveheart, Latigo, BlossomHill Perform Well In Public Market Debuts
(3d)
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid
(3d)
SMID Cap Earnings In Brief: Sarepta, Arcturus, Iovance, BioMarin, Viridian & Roivant
(4d)
IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
(4d)
Executives On The Move: Five CEOs And Six CMOs Among This Week’s Changes
(4d)
Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
(4d)
Biocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents
(4d)
Asia Deal Watch: AstraZeneca Teams With CSPC On Biologics Manufacturing In China
(4d)
Insmed Finds Itself In Rare Company: A SMID Cap With A Blockbuster Launch
(4d)
Orzeyful Approval Gives Takeda First Of Three Much-Needed Growth Products
(5d)
Merck KGaA Bets On Rare Diseases And Life Science To Drive Growth
(5d)
LifeMine’s Plans Mushroom With Capital Raise For Phase II Organ Transplant Study
(5d)
Phase III Data Stoke Arrowhead’s Rivalry With Ionis
(5d)